enVVeno Medical Corporation
enVVeno Medical Corporation (NVNBW) Stock Overview
Explore enVVeno Medical Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7M
P/E Ratio
-0.38
EPS (TTM)
$-1.95
ROE
-0.51%
NVNBW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of enVVeno Medical Corporation (NVNBW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.17.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.38 and a market capitalization of 7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Robert A. Berman
37
Irvine, DE
2021